0001799011 false 0001799011 2022-11-30 2022-11-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 30, 2022

 

LUCID DIAGNOSTICS INC.
(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-40901   82-5488042

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

One Grand Central Place, Suite 4600, New York, New York   10165
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (212) 949-4319

 

N/A
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share   LUCD   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

  

Item 3.02. Unregistered Sales of Equity Securities.

 

Management Services Agreement

 

As previously disclosed, Lucid Diagnostics Inc. (the “Company”) and PAVmed Inc. (“PAVmed”), its parent company, have since the Company’s formation been party to a management services agreement (as amended to date, the “MSA”). Pursuant to the MSA, PAVmed provides management and oversight of certain of the Company’s activities and makes certain resources available to the Issuer. Under the MSA, the Company currently pays a fee of $550,000 per month in consideration of such services and resources. PAVmed may elect to receive payment of the monthly fee under the MSA in cash or in shares of the Company’s common stock, with such shares valued at the volume weighted average price during the final ten trading days of the applicable month (subject to a floor price of $0.70 per share). However, in no event will PAVmed be entitled to receive under the MSA more than 7,709,836 shares of the Company’s common stock. In accordance with the MSA, on November 30, 2022, PAVmed has elected to receive payment of $1,650,000 in monthly fees under the MSA (in the amount of $550,000 for each of July 2022, August 2022 and September 2022) through the issuance of 750,818 shares of Common Stock (197,656 shares for July 2022, 221,952 shares for August 2022 and 331,210 shares for September 2022).

 

PBERA

 

On November 30, 2022, the Company and PAVmed entered into a payroll and benefit expense reimbursement agreement (the “PBERA”). Historically, PAVmed has paid for certain payroll and benefit-related expenses in respect of the Company’s personnel on behalf of the Company, and the Company has reimbursed PAVmed for the same. Pursuant to the PBERA, PAVmed will continue to pay such expenses, and the Company will continue to reimburse PAVmed for the same. The PBERA now provides that the expenses will be reimbursed on a quarterly basis or at such other frequency as the parties may determine, in cash or, subject to approval by the board of directors of each of PAVmed and the Company, in shares of the Company’s common stock, with such shares valued at the volume weighted average price of such stock during the final ten trading days preceding the later of the two dates on which such stock issuance is approved by the board of directors of each of PAVmed and the Company (subject to a floor price of $0.40 per share), or in a combination of cash and shares. However, in no event shall the Company issue any shares of its common stock to PAVmed in satisfaction of all or any portion of the expenses if the issuance of such shares of its common stock would exceed the maximum number of shares of common stock that the Issuer may issue under the rules or regulations of The Nasdaq Stock Market LLC (“Nasdaq”), unless the Company obtains the approval of its stockholders as required by the applicable rules of the Nasdaq for issuances of shares of its common stock in excess of such amount. In accordance with the PBERA, on November 30, 2022, PAVmed elected for the Company to reimburse PAVmed for $2,719,430 in accrued and unreimbursed payroll and benefit-related expenses paid by PAVmed on behalf of the Company through the third quarter of 2022 through the issuance of 1,479,326 shares of the Company’s common stock.

 

CapNostics Assignment Agreement

 

As previously disclosed, on October 5, 2021, PAVmed Subsidiary Corp., a wholly owned subsidiary of PAVmed (“PAVmed Sub”), acquired 100% of the outstanding membership interest of CapNostics, LLC from a third party, for a purchase price of approximately $2,100,000. Also as previously disclosed, effective as of April 1, 2022, pursuant to an assignment agreement (as amended and supplemented to date, the “CapNostics Assignment Agreement”) between PAVmed Sub and the Company, PAVmed Sub assigned the interests to the Company and, in consideration for the interests, the Company agreed to pay to PAVmed Sub an amount in cash equal to the purchase price paid by PAVmed Sub to the third party. On November 30, 2022, pursuant to a supplement to the CapNostics Assignment Agreement, the Company, PAVmed Sub and PAVmed agreed that the Company would pay the price for the interests through the issuance to PAVmed of 1,145,086 shares of the Company’s common stock.

 

The shares of the Company’s common stock issuable under the MSA, PBERA and the CapNostics Assignment Agreement are being offered and sold in transactions exempt from registration under the Securities Act, in reliance on the exemption afforded under Section 4(a)(2) thereof.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.   Description
     
10.1   Sixth Amendment to Management Services Agreement, dated as of July 1, 2022, by and between PAVmed Inc. and Lucid Diagnostics Inc.
     
10.2   Payroll and Benefit Expense Reimbursement Agreement, dated as of November 30, 2022, by and between PAVmed Inc. and Lucid Diagnostics Inc.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 2, 2022 LUCID DIAGNOSTICS INC.
     
  By: /s/ Dennis McGrath
    Dennis McGrath
    Chief Financial Officer

 

 

 

 

Exhibit 10.1

 

SIXTH AMENDMENT TO MANAGEMENT SERVICES AGREEMENT

 

Reference is made to the Management Services Agreement (as amended from time to time, the “Agreement”; capitalized terms used but not defined herein have the meaning ascribed to them in the Agreement), dated as of May 12, 2018, by and between PAVmed Inc., a Delaware corporation (“PAVmed”) and Lucid Diagnostics Inc., a Delaware corporation (“Lucid Diagnostics”).

 

WHEREAS, as set forth in Section 3(b) of the Agreement, the parties have considered in good faith an adjustment to the Service Fee and hereby wish to amend the Agreement to reflect such adjustment as set forth herein.

 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereby agree as follows:

 

1. Amendment. Effective July 1, 2022, Section 3(a) of the Agreement is hereby deleted in its entirety and replaced with the following:

 

“In consideration of the Services, Lucid Diagnostics shall pay to PAVmed a fee of $550,000 per month, plus all reasonable, out-of-pocket expenses incurred by PAVmed in connection with the performance of the Services (the “Service Fee”). The Service Fee shall be payable on a monthly basis on the first day of the month following the month in which the Services in respect thereof have been provided and shall be payable, at PAVmed’s election, in cash or shares of Lucid Diagnostics common stock (which shall be valued at the volume weighted average price of such stock during the final ten trading days of the applicable month, but in no event shall such shares be valued at a price per share lower than $0.70 (as may be equitably adjusted for stock dividends, subdivisions, combinations, or other similar events affecting the Lucid Diagnostics common stock as a whole)), or a combination of the two. If PAVmed does not notify Lucid Diagnostics of its election as to the form of payment of the Service Fee at least two (2) business days before the Service Fee is due, PAVmed shall be deemed to have elected that the fee for such month be paid in shares of Lucid common stock. Notwithstanding the foregoing, in no event shall Lucid Diagnostics issue any shares of its common stock to PAVmed in satisfaction of all or any portion of any Service Fee if the issuance of such shares of common stock would exceed the maximum number of shares of common stock which Lucid Diagnostics may issue hereunder without breaching Lucid Diagnostics’ obligations under the rules or regulations of The Nasdaq Stock Market LLC (“Nasdaq”), unless Lucid Diagnostics obtains the approval of its stockholders as required by the applicable rules of the Nasdaq for issuances of shares of its common stock hereunder in excess of such amount. If PAVmed elects for all or any portion of the Service Fee to be paid in cash, Lucid Diagnostics may defer payment of all or any portion of the Service Fee payable in cash until such time that it has sufficient cash to pay such amount, and in such case any unpaid Service Fee shall continue to accrue so long as it remains unpaid.”

 

2. Terms of Agreement. Except as expressly set forth in this amendment, the terms of the Agreement remain unchanged and in full force and effect.

 

3. Entire Agreement. This amendment, together with the Agreement, contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

[remainder of page left intentionally blank]

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this agreement as of August 11, 2022.

 

AGREED AND ACCEPTED BY:

 

PAVMED INC.   LUCID DIAGNOSTICS INC.
         
By: /s/ Lishan Aklog, M.D.   By: /s/ Lishan Aklog, M.D.
Name: Lishan Aklog, MD   Name: Lishan Aklog, MD
Title: Chairman and Chief Executive Officer   Title: Chairman and Chief Executive Officer

 

 

 

 

Exhibit 10.2

 

PAYROLL AND BENEFIT EXPENSE REIMBURSEMENT agreement

 

This Payroll and Benefit Expense Reimbursement Agreement, dated as of November 30, 2022 (this “Agreement”), is by and between PAVmed Inc., a Delaware corporation (“PAVmed”), and Lucid Diagnostics Inc., a Delaware corporation (“Lucid Diagnostics”).

 

WHEREAS, Lucid Diagnostics is a subsidiary of PAVmed; and

 

WHEREAS, PAVmed desires to pay for certain payroll and benefit-related expenses in respect Lucid Diagnostics personnel on behalf of Lucid Diagnostics, and Lucid Diagnostics desires to reimburse PAVmed for the same.

 

NOW, THEREFORE, the parties hereby agree as follows:

 

1. Covered Expenses

 

(a) General. Upon the terms and subject to the conditions contained herein, during the term of this Agreement, PAVmed has paid, and will continue to pay, for certain payroll and benefit-related expenses (“Covered Expenses”) in respect of Lucid Diagnostics personnel on behalf of Lucid Diagnostics, and Lucid Diagnostics desires to reimburse PAVmed for the same.

 

(b) Records. PAVmed shall maintain appropriate and accurate books and records pertaining to the Covered Expenses it incurs in respect hereof, and will make such books and records available to Lucid Diagnostics and its representatives at reasonable times and upon reasonable notice.

 

2. Term and Termination. The term of this Agreement shall commence on the date hereof and shall continue until such time as either party gives the other party written notice of its election to terminate this Agreement.

 

3. Reimbursement. Lucid Diagnostics shall reimburse PAVmed for all Covered Expenses paid by PAVmed in respect of Lucid Diagnostics personnel on behalf of Lucid Diagnostics in accordance with the terms hereof. The Covered Expenses shall be reimbursed on a quarterly basis or at such other frequency as the parties may determine, in cash or, subject to approval by the board of directors of each of PAVmed and Lucid Diagnostics, shares of Lucid Diagnostics common stock (which shall be valued at the volume weighted average price of such stock during the final ten trading days preceding the later of the two dates on which such stock issuance is approved by the board of directors of each of PAVmed and Lucid Diagnostics, but in no event shall such shares be valued at a price per share lower than $0.40 (as may be equitably adjusted for stock dividends, subdivisions, combinations, or other similar events affecting the Lucid Diagnostics common stock as a whole)), or a combination of the two. If PAVmed does not notify Lucid Diagnostics of its election as to the form of payment of the Covered Expenses at least sixty (60) days after the end of the quarter in respect of which such payment is due, PAVmed shall be deemed to have elected that the fee for such month be paid in shares of Lucid Diagnostics common stock. Notwithstanding the foregoing, in no event shall Lucid Diagnostics issue any shares of its common stock to PAVmed in satisfaction of all or any portion of any Covered Expenses if the issuance of such shares of common stock would exceed the maximum number of shares of common stock which Lucid Diagnostics may issue hereunder without breaching Lucid Diagnostics’ obligations under the rules or regulations of The Nasdaq Stock Market LLC (“Nasdaq”), unless Lucid Diagnostics obtains the approval of its stockholders as required by the applicable rules of the Nasdaq for issuances of shares of its common stock hereunder in excess of such amount. If PAVmed elects for all or any portion of the Covered Expenses to be paid in cash, Lucid Diagnostics may defer payment of all or any portion of the Covered Expenses payable in cash until such time that it has sufficient cash to pay such amount, and in such case any unpaid Covered Expenses shall continue to accrue (without interest) so long as they remain unpaid.

 

 

 

 

4. Tax Matters.

 

(a) Lucid Diagnostics will be liable for and will reimburse PAVmed or pay, as applicable, any applicable sales or similar taxes with respect to the Covered Expenses.

 

(b) If Lucid Diagnostics is required to withhold from any amount owed to PAVmed for any taxes for which PAVmed is responsible, the amount withheld shall be subtracted from the amount owed by Lucid Diagnostics and PAVmed will receive the amount remaining after the tax withheld.

 

5. Limitation of Liability

 

(a) General Limitation. PAVmed shall not be liable to Lucid Diagnostics or any other person for any act or omission or any alleged act or omission in connection with its performance of (or failure to perform) its obligations under this Agreement, except where such act or omission or alleged act or omission is finally judicially determined to have resulted from the gross negligence or willful misconduct of PAVmed. In no event shall PAVmed have liability under or in respect of this Agreement in the aggregate in excess of the Covered Expenses actually reimbursed by Lucid Diagnostics.

 

(b) Force Majeure. PAVmed shall not be liable to Lucid Diagnostics or any other person for any act or omission or any alleged act or omission in connection with its performance of (or failure to perform) its obligations under this Agreement from any cause beyond its reasonable control, including without limitation acts of God, acts of civil or military authority, embargoes, epidemics, war, terrorist acts, riots, insurrections, fires, explosions, earthquakes, nuclear accidents, floods, strikes, and power blackouts.

 

(c) No Consequential Damages. Neither party shall have any liability to the other party hereunder for any consequential, exemplary, incidental, indirect, prospective, punitive, remote or speculative damages.

 

(d) Indemnification. Lucid Diagnostics shall indemnify, defend and hold harmless PAVmed, its affiliates, officers, directors, employees, agents and representatives (collectively, the “Indemnified Persons”) from and against any and all losses, liabilities, claims, damages, actions, fines, penalties, expenses or costs (including court costs and reasonable attorneys’ fees) suffered or incurred by any such Indemnified Person relating to any claim of a third party arising from or in connection with PAVmed’s performance of (or failure to perform) its obligations under this Agreement, except where such performance (or non-performance) is finally judicially determined to have resulted from the gross negligence or willful misconduct of such Indemnified Person.

 

(e) Survival. The parties hereto acknowledge and agree that the provisions of this Section 5 shall survive the termination of this Agreement.

 

2

 

 

6. Dispute Resolution

 

Any dispute or controversy among the parties hereto arising out of or relating to this Agreement shall be finally settled by arbitration in the City of New York, NY, administered by the American Arbitration Association. Judgment on the award may be enforced in any court of competent jurisdiction. The parties expressly authorize the arbitrator to require that all or a portion of the prevailing party’s fees and expenses in the arbitration be allocated to and borne by the other party, if the arbitrator determines that the other party’s positions were sufficiently non-meritorious so as to make such allocation equitable.

 

7. Miscellaneous

 

(a) Entire Agreement. This Agreement sets forth the entire agreement of the parties with respect to the subject matter hereof, and supersedes all other agreements, arrangements or understandings, written or oral, with respect to such subject matter.

 

(b) Headings. Headings to Sections herein are for the convenience of the parties only, and are not intended to affect the meaning or interpretation of this Agreement.

 

(c) Amendments. This Agreement may not be amended except by a written instrument signed by both of the parties.

 

(d) Assignment. Neither party may assign its rights or delegate its duties hereunder without the prior written consent of the other party. This Agreement will be binding upon, and will inure to the benefit of, the successors and permitted assigns of the parties.

 

(e) Relationship of the Parties. The parties are independent contractors, and are not partners or joint venturers, and nothing contained herein is intended to create an agency relationship or a partnership or joint venture.

 

(f) Employees. Employees or subcontractors of PAVmed shall not be considered employees of Lucid Diagnostics by reason of this Agreement.

 

(g) Notices. All notices or other communications to be given hereunder to a party shall be in writing and shall be sent by delivery in person, by nationally recognized courier service, by telecopy or by electronic mail. Any notice given hereunder shall be deemed to have been given upon the earlier of: (i) receipt and (ii) two days after being sent by a nationally recognized courier service, return receipt or proof of delivery requested.

 

3

 

 

(h) Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, without regard to conflicts of law rules.

 

(i) No Waiver. No failure or delay on the part of any party hereto in exercising any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy. No waiver of any provision of this Agreement shall be effective unless the same shall be made in writing and signed by the party against whom such waiver is sought to be enforced.

 

(j) Severability. If it is finally determined that any term or provision of this Agreement is invalid or unenforceable, the parties agree that the court making the determination of invalidity or unenforceability shall reduce the scope, duration, or area of the term or provision, delete specific words or phrases, or replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified.

 

(k) No Third-Party Beneficiaries. Except for the right of PAVmed’s affiliates, officers, directors, employees, agents and representatives to enforce their rights to indemnification under Section 5(d), this Agreement benefits solely the parties to this Agreement and their respective permitted successors and assigns and nothing in this Agreement, express or implied, confers on any other person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

 

(l) Counterparts. This Agreement may be executed in two counterparts.

 

[Signature page follows]

 

4

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

 

  PAVMED INC.
     
  By: /s/ Lishan Aklog, M.D.
  Name: Lishan Aklog, M.D.
  Title: Chairman and Chief Executive Officer
     
  LUCID DIAGNOSTICS INC.
     
  By: /s/ Lishan Aklog, M.D.
  Name: Lishan Aklog, M.D.
  Title: Chairman and Chief Executive Officer